Behind skin cancer, breast cancer is the most common cancer among American women, according to the American Cancer Society, which estimates that over 40,000 women will die from breast cancer this year alone, while over 230,000 new cases will be diagnosed.
Mammograms and regular self-exams are useful tools in helping detect breast cancer, but what if the process was even easier? KMD Biomarker Diagnostics is developing an “accurate, early-stage detection of breast cancer,” according to its campaign. Mammograms fail to detect cancer early enough, missing a fair number of emerging cases. With KMD’s simple urine test, which tests for metabolites, women will have access to earlier detection through a non-invasive means.
Created in part by two bio-scientists and self-funded, the group aims to raise enough funding to fully determine which metabolites in urine are indicative of breast cancer through continued research.
Based out of Boise, ID, they have a fundraising goal of $180,000
You can support KMD on Indiegogo.
As one of MedTech Boston's editorial interns, Lisa covers events, contributes photography and feature stories to the site and manages social media. She recently received her Master of Science in Journalism from Boston University. Lisa also earned her Bachelor of Arts from BU, with a degree in English and Philosophy. She has written for multiple campus publications, in addition to interning at Boston magazine.
Send this to a friend